JenaValve Technology said today that it named former ReVision Optics prez & CEO John Kilcoyne as its new chief executive officer, effective immediately, replacing Dr. Victoria Carr-Brendell, who has taken up an executive leadership position with Sonova Holding AG (SIX:SOON). Prior to his time at ReVision Optics, Kilcoyne served as prez & CEO at Micrus Endovascular where he […]
Micrus Endovascular Corp.
Johnson & Johnson (NYSE:JNJ) closed its $480 million cash deal to acquire Micrus Endovascular Corp. (NSDQ:MEND), a San Jose, Calif.-based maker of cerebral vascular devices.
San Jose, Calif.-based Micrus specializes in “bioactive” coils used to treat ischemic stroke and aneurysms.
Johnson & Johnson (NYSE: JNJ) agreed to pay $480 million in cash to acquire Micrus Endovascular Corp. (NSDQ:MEND), a San Jose, Calif.-based maker of cerebral vascular devices.
Micrus specializes in "bioactive" coils used to treat ischemic stroke and aneurysms, according to a press release. The deal is expected to close during the second half of the year.
Micrus Endovascular Corp. (NSDQ:MEND) posted third-quarter sales of $22.8 million for the three months ended Dec. 31, 2009, up 24.4 percent compared with $18.3 million during the same period in 2008. The company swung from a net loss of $2.3 million during Q3 2009 to net income of $3.3 million during Q3 2010:
Micrus Endovascular Reports Fiscal Third Quarter Revenues of $22.8 Million and Diluted EPS of $0.20
Record Quarterly Revenues up 24%; Double-digit Revenue Growth in All Major Geographic Regions; Fourth Consecutive Quarter of Profitability